
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tri-Ax
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Halberd Corp’s TBI Nasal Spray Shows Promising Phase II Test Results
Details : Halberd's Tri-Ax™ is a nasal spray aimed at mitigating traumatic brain injury (TBI). It shows promising Phase II results, improving motor function after head trauma.
Product Name : Tri-Ax
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 24, 2024
Lead Product(s) : Tri-Ax
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Partnership
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
Details : Under the agreement, the testing will focus on Halberd's patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining head trauma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, the testing will focus on Halberd's patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining head trauma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Details : Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
